|

Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

RECRUITINGSponsored by Peking University Third Hospital
Actively Recruiting
SponsorPeking University Third Hospital
Started2017-01-01
Est. completion2026-12-30
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06587022

Summary

The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;
* Patients with sufficent pre-treatment imaging data
* Patients who can cooperate with imaging review and follow-up after radiotherapy.

Exclusion Criteria:

* Patients with an expected survival of less than 3 months;
* Patients with second-course radiotherapy;
* Patients with physical conditions that cannot tolerate stereotactic radiotherapy;
* Patients with extensive spinal metastasis and no local therapeutic value

Conditions2

CancerSpinal Tumor

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.